AES 14
Alternative Names: Aesgen-14; E 6014; L-glutamine suspension - Aesgen; Saforis; Uptake-enhanced L-glutamine suspensionLatest Information Update: 05 Nov 2023
At a glance
- Originator MGI Pharma
- Developer Eisai Co Ltd
- Class Anti-inflammatories; Antianaemics; Antihyperglycaemics; Basic amino acids; Diamino amino acids; Neutral amino acids; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Stomatitis
Most Recent Events
- 15 May 2012 Discontinued - Phase-III for Stomatitis in USA (PO)
- 01 Nov 2011 Phase III development is ongoing in US
- 29 Jan 2008 MGI Pharma has been acquired by Eisai